clinical trials

Senhwa’s CX-5461 Gains FDA IND Clearance and NCI Support to Advance in MYC-Driven Lymphoma

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has...

By cGxPwire Editor
September 5, 2025

.Clinical Bio-Pharma

IDEAYA Biosciences Enrolls First Patient in Phase 1/2 Combination Trial of IDE397 and Trodelvy® in MTAP-Deletion NSCLC

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company, announced the enrollment of the first patient in its...

By cGxPwire Editor
September 4, 2025

.Clinical Bio-Pharma

Oncolytics Biotech Shows Favorable Safety for Pelareorep in GI Tumors

SAN DIEGO, Sept. 2, 2025 – Oncolytics Biotech® Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company, announced updated clinical safety...

By cGxPwire Editor
September 2, 2025

.gov

FDA Approves Updated 2025–2026 COVID-19 Vaccines from Pfizer, Moderna, and Novavax

The FDA has approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax for the 2025-2026 season, targeting high-risk groups....

By cGxPwire Editor
August 27, 2025

.gov

FDA Ends Broad Emergency Authorization, Approves Updated COVID-19 Vaccines

The FDA approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax while ending broad Emergency Use Authorization. Eligibility is...

By cGxPwire Editor
August 27, 2025

Find Jobs Across Pharma, Biotech & Life Sciences

Discover verified job opportunities from top companies worldwide. Apply easily and grow your career in the life sciences industry.

M&A

AbbVie Acquires Gilgamesh Pharmaceuticals’ Bretisilocin, A Novel Psychedelic Therapy for Major Depressive Disorder

AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate bretisilocin (GM-2505), a next-generation...